Pancreatic Ductal Adenocarcinoma (PDAC) is the third leading cause of cancer-related deaths in the U.S. Both rare and common germline variants contribute to PDAC risk. Here, we fine-map and functionally characterize a common PDAC risk signal at chr1p36.33 (tagged by rs13303010) identified through a genome wide association study (GWAS). One of the fine-mapped SNPs, rs13303160 (ORâ=â1.23 (95% CI 1.15-1.32), P-valueâ=â2.74Ã10(-9), LD r(2)â=â0.93 with rs13303010 in 1000âG EUR samples) demonstrated allele-preferential gene regulatory activity in vitro and binding of JunB and JunD in vitro and in vivo. Expression Quantitative Trait Locus (eQTL) analysis identified KLHL17 as a likely target gene underlying the signal. Proteomic analysis identified KLHL17 as a member of the Cullin-E3 ubiquitin ligase complex with vimentin and nestin as candidate substrates for degradation in PDAC-derived cells. In silico differential gene expression analysis of high and low KLHL17 expressing GTEx pancreas samples suggested an association between lower KLHL17 levels (risk associated) and pro-inflammatory pathways. We hypothesize that KLHL17 may mitigate cell injury and inflammation by recruiting nestin and vimentin for ubiquitination and degradation thereby influencing PDAC risk.
Allelic effects on KLHL17 expression underlie a pancreatic cancer genome-wide association signal at chr1p36.33.
KLHL17 表达的等位基因效应是 chr1p36.33 处胰腺癌全基因组关联信号的基础
阅读:8
作者:Connelly Katelyn E, Hullin Katherine, Abdolalizadeh Ehssan, Zhong Jun, Eiser Daina, O'Brien Aidan, Collins Irene, Das Sudipto, Duncan Gerard, Chanock Stephen J, Stolzenberg-Solomon Rachael Z, Klein Alison P, Wolpin Brian M, Hoskins Jason W, Andresson Thorkell, Smith Jill P, Amundadottir Laufey T
| 期刊: | Nature Communications | 影响因子: | 15.700 |
| 时间: | 2025 | 起止号: | 2025 Apr 30; 16(1):4055 |
| doi: | 10.1038/s41467-025-59109-2 | 研究方向: | 信号转导 |
| 疾病类型: | 胰腺癌 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
